JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB261787

Human LMNA (Lamin A) knockout HeLa cell line

Be the first to review this product! Submit a review

|

(0 Publication)

LMNA KO cell line available to order. KO validated by Western blot. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, 19 bp deletion in exon 4 and 1 bp deletion in exon 4 and 22 bp deletion in exon 4. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.
5 Images
Western blot - Human LMNA (Lamin A) knockout HeLa cell line (AB261787)
  • WB

Supplier Data

Western blot - Human LMNA (Lamin A) knockout HeLa cell line (AB261787)

Lanes 1-2 : Merged signal (red and green). Green - ab232730 observed at 7075 kDa. Red - loading control ab181602 observed at 37 kDa.

ab232730 Anti-Lamin A + C antibody [WL4G10] was shown to specifically react with Lamin A + C in wild-type HeLa cells. Loss of signal was observed when knockout cell line ab261787 (knockout cell lysate ab256979) was used. Wild-type and Lamin A + C knockout samples were subjected to SDS-PAGE. ab232730 and Anti-GAPDH antibody[EPR16891] - Loading Control (ab181602) were incubated overnight at 4° at 1 in 1000 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Mouse IgG H&L (IRDye® 800CW) preadsorbed (ab216772) and Goat Anti-Rabbit IgG H&L (IRDye® 680RD) preadsorbed (ab216777) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.

All lanes:

Western blot - Anti-Lamin A + Lamin C antibody [WL4G10] (<a href='/en-us/products/primary-antibodies/lamin-a-lamin-c-antibody-wl4g10-ab232730'>ab232730</a>) at 1/1000 dilution

Lane 1:

Wild-type HeLa cell lysate at 20 µg

Lane 2:

Lamin A + C knockout HeLa cell lysate at 20 µg

Lane 2:

Western blot - Human LMNA (Lamin A) knockout HeLa cell line (ab261787)

Secondary

All lanes:

Western blot - Goat anti-Mouse IgG H&L (IRDye® 800CW) preadsorbed (<a href='/en-us/products/secondary-antibodies/goat-mouse-igg-h-l-irdye-800cw-preadsorbed-ab216772'>ab216772</a>) at 1/20000 dilution

Predicted band size: 74 kDa

Observed band size: 70 kDa,75 kDa

false

Western blot - Human LMNA (Lamin A) knockout HeLa cell line (AB261787)
  • WB

Lab

Western blot - Human LMNA (Lamin A) knockout HeLa cell line (AB261787)

Lanes 1-2 : Merged signal (red and green). Green - ab238303 observed at 74 kDa. Red - loading control ab181602 observed at 37 kDa.

ab238303 Anti-Lamin A + C antibody [4C11] was shown to specifically react with Lamin A + C in wild-type HeLa cells. Loss of signal was observed when knockout cell line ab261787 (knockout cell lysate ab256979) was used. Wild-type and Lamin A + C knockout samples were subjected to SDS-PAGE. ab238303 and Anti-GAPDH antibody[EPR16891] - Loading Control (ab181602) were incubated overnight at 4° at 1 μg/ml and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Mouse IgG H&L (IRDye® 800CW) preadsorbed (ab216772) and Goat Anti-Rabbit IgG H&L (IRDye® 680RD) preadsorbed (ab216777) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.

All lanes:

Western blot - Anti-Lamin A + Lamin C antibody [4C11] (<a href='/en-us/products/primary-antibodies/lamin-a-lamin-c-antibody-4c11-ab238303'>ab238303</a>) at 1 µg/mL

Lane 1:

Wild-type HeLa cell lysate at 20 µg

Lane 2:

Lamin A + C knockout HeLa cell lysate at 20 µg

Lane 2:

Western blot - Human LMNA (Lamin A) knockout HeLa cell line (ab261787)

Secondary

All lanes:

Western blot - Goat anti-Mouse IgG H&L (IRDye® 800CW) preadsorbed (<a href='/en-us/products/secondary-antibodies/goat-mouse-igg-h-l-irdye-800cw-preadsorbed-ab216772'>ab216772</a>) at 1/20000 dilution

Predicted band size: 74 kDa

Observed band size: 74 kDa

false

Sanger Sequencing - Human LMNA (Lamin A) knockout HeLa cell line (AB261787)
  • Sanger seq

Unknown

Sanger Sequencing - Human LMNA (Lamin A) knockout HeLa cell line (AB261787)

Allele-3 : 22 bp deletion in exon 4.

Sanger Sequencing - Human LMNA (Lamin A) knockout HeLa cell line (AB261787)
  • Sanger seq

Unknown

Sanger Sequencing - Human LMNA (Lamin A) knockout HeLa cell line (AB261787)

Allele-2 : 1 bp deletion in exon 4.

Sanger Sequencing - Human LMNA (Lamin A) knockout HeLa cell line (AB261787)
  • Sanger seq

Unknown

Sanger Sequencing - Human LMNA (Lamin A) knockout HeLa cell line (AB261787)

Allele-1 : 19 bp deletion in exon 4.

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Form

Liquid

form

Knockout validation

Sanger Sequencing,Western blot

Mutation description

Knockout achieved by using CRISPR/Cas9, 19 bp deletion in exon 4 and 1 bp deletion in exon 4 and 22 bp deletion in exon 4

Antibiotic resistance

Puromycin 1µg/mL

Disease

Adenocarcinoma

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "WB": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab261787-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab261787 Human LMNA (Lamin A) knockout HeLa cell line", "number":"AB261787-CMP01" }, { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB261787-CMP02" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab261787-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab261787 Human LMNA (Lamin A) knockout HeLa cell line", "number":"AB261787-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
LMNA
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing, Western blot
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Lamin A also known as LMNA is a type of lamin protein integral to the nuclear architecture. It has a molecular weight of approximately 70 kDa. This protein localizes mainly to the nuclear lamina a dense fibrillar network inside the inner nuclear membrane found across various cell types. Lamin A serves as a structural scaffold mediating nuclear stability and rigidity. It also plays a role in chromatin organization supporting overall nuclear functions.
Biological function summary

The lamin molecule interacts with several nuclear components forming part of the nuclear lamina complex. It anchors chromatin material and regulates DNA replication and repair. Lamin A protein also modulates gene expression through interactions with transcription factors. Beyond structural support it influences cell cycle progression and differentiation impacting cellular mechanotransduction and signaling processes.

Pathways

Lamin A performs critical functions within the cell cycle and apoptotic pathways. Its interactions with the retinoblastoma protein (pRB) and other cyclin-dependent kinases control cell cycle checkpoints and progression. Moreover lamin A connects with proteins involved in signaling pathways like MAPK which relate to stress responses and cellular growth. These interactions highlight its dynamic involvement in maintaining cell health and proliferation.

Mutations in the lamin A gene associate closely with Hutchinson-Gilford Progeria Syndrome and Emery-Dreifuss Muscular Dystrophy. In these conditions altered lamin A protein affects nuclear shape and chromatin layout disrupting transcriptional regulation. The mutated lamin A protein interacts differently with binding partners like emerin contributing to muscle adipose tissue and multi-system abnormalities. This highlights the critical role lamin A plays in maintaining normal cellular function across life stages.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com